Combination chemotherapy for metastatic urinary bladder cancer with 5-FU, vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate

Twenty-two patients with advanced primary bladder cancer with metastatic lesions were treated with a combination of 5-FU, vincristine, bleomycin, mitomycin, and methotrexate. Complete and partial responses were achieved in two (9%) and five (23%) patients, respectively. The overall response rate was 32%. The major toxic effects were myelosuppression and mild gastrointestinal symptoms.